Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Corticosteroids for IRIS in PML on Natalizumab
2010-020369-26Phase 4Completed
- Sponsor
- Biogen
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone and prednisolone in immune reconstitution inflammatory syndrome (IRIS), progressive multifocal leukoencephalopathy (PML) and multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Karnofsky Performance Status Scale. Started Aug 2010; status: completed.
02
Drugs
methylprednisoloneprednisolone
03
Conditions
immune reconstitution inflammatory syndrome (IRIS)progressive multifocal leukoencephalopathy (PML)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-020369-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020369-26.